Clinical Studies for Biotech and Medical Devices: Building 510(k) and De Novo-Ready Evidence

Biotech and medical device companies live and die on the strength of their clinical evidence package. Unlike a supplement brand that needs FTC-defensible substantiation, a Class II or Class III device company needs evidence that survives FDA review, peer review, and (for many) payor coverage decisions. The bar is meaningfully higher, the timelines are longer, and the cost of getting it wrong is a delayed clearance or a denied claim. This guide covers what a biotech or medical device company should actually be designing for, and how to avoid the most expensive mistakes we see at the protocol stage. Start with the regulatory pathway Every clinical evidence plan starts with the regulatory pathway, not the study design. The right design for a 510(k) substantial equivalence submission is not the same as the right design for a De Novo or PMA pathway, and neither is the right design for a CE marking under the EU MDR. Get a regulatory consult and a predicate analysis on paper before you scope the study. 510(k): Performance testing, plus clinical evidence when needed to demonstrate substantial equivalence. De Novo: Clinical evidence demonstrating safety and effectiveness for a novel indication; expect a pre-submission (Q-Sub) meeting. PMA: Pivotal trial with primary effectiveness and safety endpoints, IDE required. EU MDR: Clinical Evaluation Report (CER) supported by clinical investigation under ISO 14155. GCP, ICH E6, and 21 CFR Part 11 For any device study intended to support a regulatory submission, the protocol must be Good Clinical Practice (GCP) compliant under ICH E6 (R3). Electronic data capture must be 21 CFR Part 11 compliant — audit trails, access controls, validated systems, and signed data exports. This is not optional for FDA-facing work, and reviewers will reject submissions built on non-compliant infrastructure. Endpoints, biomarkers, and pre-registration Pre-register your primary and secondary endpoints on ClinicalTrials.gov before enrolling the first subject. Reviewers and journals both check. For biomarker-driven studies, partner with a CLIA-certified lab and pre-specify your assay, your acceptance criteria, and your statistical analysis plan (SAP). Common biomarker categories we run for biotech and device sponsors: genomic and transcriptomic panels, proteomic and metabolomic profiling, continuous glucose monitoring, ECG and arrhythmia detection, sleep architecture (PSG and home sleep tests), and digital biomarkers from wearables. Multi-site execution and IRB strategy Most pivotal device studies require multi-site execution for diversity and generalizability. A central IRB (single IRB review under the Common Rule) is now the standard for multi-site studies in the US and dramatically shortens the activation timeline compared to local IRB-by-IRB review. Build your monitoring plan, adverse event reporting workflow, and data safety monitoring board (DSMB) charter before activation. How Citruslabs supports biotech and device sponsors Our biotech and medical devices practice runs GCP-compliant, IRB-approved, 21 CFR Part 11-validated studies for diagnostic devices, therapeutic devices, digital therapeutics, and biotech sponsors with novel ingredients or delivery systems. We design for the regulatory pathway you are pursuing, run multi-site execution where required, and deliver data and reports formatted for FDA submission, peer-reviewed publication, and payor evidence dossiers.